Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 305

1.

Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.

Samri A, Charpentier C, Diallo MS, Bertine M, Even S, Morin V, Oudin A, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaut R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, Autran B; ANRS CO5 IMMUNOVIR-2 Study Group.

PLoS Pathog. 2019 May 16;15(5):e1007758. doi: 10.1371/journal.ppat.1007758. eCollection 2019 May.

2.

B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.

Lucar O, Sadjo Diallo M, Bayard C, Samri A, Tarantino N, Debré P, Thiébaut R, Brun-Vézinet F, Matheron S, Cheynier R, Vieillard V; ANRS CO5 IMMUNOVIR-2 Study group.

AIDS. 2019 Jan 27;33(1):23-32. doi: 10.1097/QAD.0000000000002061.

PMID:
30325780
3.

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G; France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group.

Clin Infect Dis. 2018 Sep 28;67(8):1161-1167. doi: 10.1093/cid/ciy245.

4.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIeV2e Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2869-2878. doi: 10.1093/jac/dkx210.

5.

Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.

Angin M, Wong G, Papagno L, Versmisse P, David A, Bayard C, Charmeteau-De Muylder B, Besseghir A, Thiébaut R, Boufassa F, Pancino G, Sauce D, Lambotte O, Brun-Vézinet F, Matheron S, Rowland-Jones SL, Cheynier R, Sáez-Cirión A, Appay V; ANRS CO5 IMMUNOVIR-2 Study Group.

J Immunol. 2016 Oct 1;197(7):2787-95. doi: 10.4049/jimmunol.1600693. Epub 2016 Aug 26.

6.

Tropism distribution among antiretroviral-naive HIV-2-infected patients.

Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2015 Oct 23;29(16):2209-12. doi: 10.1097/QAD.0000000000000825.

PMID:
26544584
7.

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Metzner KJ, Paredes R; CHAIN Minority HIV-1 Variants Working group.

Clin Microbiol Infect. 2016 Feb;22(2):191-200. doi: 10.1016/j.cmi.2015.10.004. Epub 2015 Oct 23.

8.

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

PLoS One. 2015 Aug 6;10(8):e0134904. doi: 10.1371/journal.pone.0134904. eCollection 2015.

9.

HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.

Charpentier C, Camacho R, Ruelle J, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Kaiser R, Descamps D, Obermeier M.

Clin Infect Dis. 2015 Oct 15;61(8):1346-7. doi: 10.1093/cid/civ572. Epub 2015 Jul 17. No abstract available.

PMID:
26187019
10.

High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2015 Apr 24;29(7):779-84. doi: 10.1097/QAD.0000000000000607.

PMID:
25985400
11.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; CHAIN Minority HIV-1 Variants Working Group.

J Antimicrob Chemother. 2015 Mar;70(3):930-40. doi: 10.1093/jac/dku426. Epub 2014 Oct 21.

12.

HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.

Visseaux B, Charpentier C, Rouard C, Fagard C, Glohi D, Tubiana R, Damond F, Brun-Vézinet F, Matheron S, Descamps D; French HIV-2 ANRS Cohort CO5.

AIDS. 2014 Sep 10;28(14):2160-2. doi: 10.1097/QAD.0000000000000373.

PMID:
25265081
13.

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4).

J Int AIDS Soc. 2014 Sep 25;17:19070. doi: 10.7448/IAS.17.1.19070. eCollection 2014.

14.

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R.

J Antimicrob Chemother. 2014 Oct;69(10):2819-25. doi: 10.1093/jac/dku211. Epub 2014 Jun 19.

PMID:
24948705
15.

Genotypic resistance profiles of HIV-2-treated patients in West Africa.

Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK; IeDEA West Africa Collaboration.

AIDS. 2014 May 15;28(8):1161-9. doi: 10.1097/QAD.0000000000000244.

16.

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D.

AIDS. 2013 Nov 28;27(18):2959-61. doi: 10.1097/QAD.0000000000000016.

PMID:
23942060
17.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Nov;68(11):2626-31. doi: 10.1093/jac/dkt238. Epub 2013 Jun 24.

PMID:
23798669
18.

Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network.

Pillay D, Albert J, Bertagnolio S, Boucher C, Brun-Vezinet F, Clotet B, Giaquinto C, Perno CF.

Antivir Ther. 2013;18(6):831-6. doi: 10.3851/IMP2650. Epub 2013 Jun 5.

PMID:
23740717
19.

Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.

Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sönnerborg A, Nachega JB.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S101-6. doi: 10.1093/infdis/jit108.

20.

Update on the human immunodeficiency virus.

Brun-Vézinet F, Charpentier C.

Med Mal Infect. 2013 May;43(5):177-84. doi: 10.1016/j.medmal.2013.03.001. Epub 2013 Apr 28. Review.

PMID:
23628423
21.

Transmitted drug resistance in French HIV-2-infected patients.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3.

PMID:
23595155
22.

Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y.

PLoS One. 2013;8(3):e59205. doi: 10.1371/journal.pone.0059205. Epub 2013 Mar 19.

23.

HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe.

Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Descamps D, Obermeier M.

Clin Infect Dis. 2013 Jun;56(11):1654-8. doi: 10.1093/cid/cit104. Epub 2013 Feb 19.

PMID:
23429380
24.

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.

Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D.

PLoS One. 2013;8(1):e54381. doi: 10.1371/journal.pone.0054381. Epub 2013 Jan 18.

25.

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D; ANRS139 TRIO Trial study group.

PLoS One. 2013;8(1):e53621. doi: 10.1371/journal.pone.0053621. Epub 2013 Jan 17.

26.

Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.

Visseaux B, Charpentier C, Taieb A, Damond F, Bénard A, Larrouy L, Chêne G, Brun-Vézinet F, Matheron S, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2013 Jan 14;27(2):292-5. doi: 10.1097/QAD.0b013e32835b8bbd.

PMID:
23095312
27.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG.

J Med Virol. 2012 Dec;84(12):1853-6. doi: 10.1002/jmv.23362.

PMID:
23080487
28.

Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study.

Casalino E, Bernot B, Bouchaud O, Alloui C, Choquet C, Bouvet E, Damond F, Firmin S, Delobelle A, Nkoumazok BE, Der Sahakian G, Viard JP, Zbar OZ, Aslangul E, Krivine A, Zundel J, Ghosn J, Nordmann P, Claessens YE, Tahi T, Riou B, Gautheret-Dejean A, Katlama C, Hausfater P, Brun-Vézinet F, Costagliola D.

PLoS One. 2012;7(10):e46437. doi: 10.1371/journal.pone.0046437. Epub 2012 Oct 2.

29.

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2013 Jan 2;27(1):69-80. doi: 10.1097/QAD.0b013e32835a10d8.

PMID:
23018441
30.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F; French ANRS HIV-2 CO5 Cohort.

Clin Infect Dis. 2012 Nov 15;55(10):1417-25. doi: 10.1093/cid/cis708. Epub 2012 Aug 20.

PMID:
22911639
31.

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.

Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P.

J Antimicrob Chemother. 2012 Sep;67(9):2231-5. doi: 10.1093/jac/dks191. Epub 2012 May 29.

PMID:
22643190
32.

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D.

J Antimicrob Chemother. 2012 Jun;67(6):1459-61. doi: 10.1093/jac/dks067. Epub 2012 Mar 1.

PMID:
22382470
33.

Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D; ANRS CO 05 HIV-2 Cohort.

J Infect Dis. 2012 Jan 1;205(1):111-20. doi: 10.1093/infdis/jir698. Epub 2011 Dec 2.

PMID:
22140264
34.

In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Antimicrob Agents Chemother. 2012 Jan;56(1):137-9. doi: 10.1128/AAC.05313-11. Epub 2011 Nov 7.

35.

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19.

PMID:
21933786
36.

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.

Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D; ANRS 127 study group.

AIDS. 2011 Nov 13;25(17):2143-8. doi: 10.1097/QAD.0b013e32834cabb9.

PMID:
21904187
37.

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05).

Antivir Ther. 2011;16(6):937-40. doi: 10.3851/IMP1826.

PMID:
21900727
38.

An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.

Damond F, Benard A, Balotta C, Böni J, Cotten M, Duque V, Ferns B, Garson J, Gomes P, Gonçalves F, Gottlieb G, Kupfer B, Ruelle J, Rodes B, Soriano V, Wainberg M, Taieb A, Matheron S, Chene G, Brun-Vezinet F; ACHI(E)V(2E) Study Group.

J Clin Microbiol. 2011 Oct;49(10):3491-7. doi: 10.1128/JCM.02389-10. Epub 2011 Aug 3.

39.

Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.

Charpentier C, Lambert-Niclot S, Larrouy L, Peytavin G, Valantin MA, Landman R, Katlama C, Yeni P, Felices M, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):e15-7. doi: 10.1097/QAI.0b013e3182139755. No abstract available.

PMID:
21734472
40.

High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.

Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D.

Antivir Ther. 2011;16(3):429-33. doi: 10.3851/IMP1754.

PMID:
21555827
41.

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, Calmy A, Balotta C, Damond F, Brun-Vezinet F, Chene G, Matheron S; ACHIEV2E Collaboration Study Group.

Clin Infect Dis. 2011 May;52(10):1257-66. doi: 10.1093/cid/cir123.

PMID:
21507923
42.

European guidelines on the clinical management of HIV-1 tropism testing.

Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing.

Lancet Infect Dis. 2011 May;11(5):394-407. doi: 10.1016/S1473-3099(10)70319-4. Epub 2011 Mar 21. Review.

PMID:
21429803
43.

Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort.

Thiébaut R, Matheron S, Taieb A, Brun-Vezinet F, Chêne G, Autran B; immunology group of the ANRS CO5 HIV-2 cohort.

AIDS. 2011 Mar 27;25(6):865-7. doi: 10.1097/QAD.0b013e328344892e.

PMID:
21358376
44.

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.

Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulié C, Wirden M, Katlama C, Yeni P, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D.

Antimicrob Agents Chemother. 2011 Apr;55(4):1754-7. doi: 10.1128/AAC.01049-10. Epub 2011 Jan 31.

45.

Benefits of resistance testing.

Descamps D, Brun-Vézinet F.

In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 9.

46.

Update of the drug resistance mutations in HIV-1: December 2010.

Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2010 Dec;18(5):156-63. Review.

47.

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28.

48.

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21.

PMID:
20965891
49.

Sensitivity and specificity of a rapid influenza diagnostic test in children and clinical utility during influenza A (H1N1) 2009 outbreak.

Angoulvant F, Bellettre X, Houhou N, Dexpert JB, Morin L, Siriez JY, Soole F, de Lauzanne A, Cohen R, Brun-Vezinet F, Alberti C, Mercier JC.

Emerg Med J. 2011 Nov;28(11):924-6. doi: 10.1136/emj.2010.098533. Epub 2010 Oct 13.

PMID:
20943835
50.

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

AIDS. 2010 Nov 13;24(17):2753-5. doi: 10.1097/QAD.0b013e32833f9e36.

PMID:
20827161

Supplemental Content

Loading ...
Support Center